Aurinia Pharmaceuticals has announced its revenue guidance for 2025, projecting a range between $250 million and $260 million. This announcement comes as the company undergoes significant operational changes aimed at improving efficiency and reducing costs, as reported by Webull.
One of the highlights from Aurinia's recent financial performance is the robust growth in LUPKYNIS sales, which resulted in a 36% increase in net product revenue year-over-year for the third quarter of 2024. To further enhance its operational efficiency, Aurinia is implementing a strategic restructuring plan that includes a workforce reduction by approximately 45%. This effort is expected to save the company over $40 million annually in cash-based operating expenses, according to information from Aurinia Pharmaceuticals' official website.
In addition to financial updates, Aurinia is focusing on its pipeline development. The company initiated a Phase 1 study of AUR200, a promising dual inhibitor targeting autoimmune disease-related cytokines, in September 2024. Investors are keeping an eye on the results expected in the first half of 2025. Meanwhile, Aurinia's share price was recently at $8.37, marking a 4.63% rise from the prior close, demonstrating a positive market reaction.